Summit Financial Strategies Inc. Lowers Stake in AbbVie Inc. $ABBV

Key Points

• Summit Financial Strategies reduced its AbbVie stake by 34.4% in the second quarter, selling 4,873 shares and retaining 9,278 shares valued at approximately $2.34 million. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie exceeded quarterly expectations with earnings of $3.65 per share and revenue of $16.99 billion, up 10.2% year over year. The company declared a quarterly dividend of $1.73 per share, equivalent to a 2.7% yield.
• Analyst sentiment remains favorable, with AbbVie carrying a “Moderate Buy” consensus rating and an average price target of $276.64. Recent positive pipeline developments include encouraging Phase 3 menstrual-migraine results for atogepant, although investors continue to monitor reliance on Skyrizi and Rinvoq and the stock’s elevated valuation.

Summit Financial Strategies Inc. cut its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 34.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,278 shares of the company's stock after selling 4,873 shares during the period. Summit Financial Strategies Inc.'s holdings in AbbVie were worth $2,335,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie in the 4th quarter worth about $28,000. Imprint Wealth LLC lifted its position in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after buying an additional 45 shares during the last quarter. Burk Holdings LLC purchased a new stake in AbbVie in the second quarter worth approximately $30,000. IFC & Insurance Marketing Inc. bought a new position in AbbVie during the fourth quarter valued at approximately $31,000. Finally, Abound Financial LLC bought a new position in AbbVie during the fourth quarter valued at approximately $32,000. Institutional investors own 70.23% of the company's stock.

AbbVie Stock Up 0.0%

Shares of NYSE ABBV opened at $257.17 on Monday. The firm's fifty day moving average is $254.46 and its 200 day moving average is $230.95. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47. The company has a market cap of $454.36 billion, a price-to-earnings ratio of 72.65, a PEG ratio of 1.16 and a beta of 0.29.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. During the same quarter in the prior year, the company posted $2.97 EPS. The firm's revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts anticipate that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. AbbVie's dividend payout ratio (DPR) is presently 195.48%.

Analyst Ratings Changes

ABBV has been the subject of a number of recent research reports. Citigroup boosted their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a report on Wednesday, July 15th. Barclays increased their target price on shares of AbbVie from $275.00 to $300.00 and gave the company an "overweight" rating in a report on Wednesday, July 29th. Wall Street Zen downgraded shares of AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Sunday, July 5th. Cantor Fitzgerald upped their price target on shares of AbbVie from $265.00 to $285.00 and gave the company an "overweight" rating in a research report on Monday, August 3rd. Finally, Sanford C. Bernstein reaffirmed a "market perform" rating on shares of AbbVie in a research note on Tuesday, June 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, AbbVie has an average rating of "Moderate Buy" and an average price target of $276.64.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 menstrual-migraine results: Atogepant met the primary and secondary endpoints in the LUNA late-stage study, demonstrating reductions in menstrual migraine days along with positive safety and efficacy results. The data could support regulatory expansion of Qulipta into an indication with no specifically approved targeted therapies, potentially broadening AbbVie’s migraine franchise. AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
• Positive Sentiment: Potentially more flexible treatment use: The results support intermittent preventive treatment around menstruation, which could expand Qulipta’s addressable market beyond continuous daily migraine prevention. Investors view the outcome as evidence of continued momentum in AbbVie’s migraine business. AbbVie Gains as Qulipta Opens a New Migraine Market
• Positive Sentiment: Additional pipeline catalyst: AbbVie completed its ECLIPSE migraine trial, setting up another potential data milestone for the company’s migraine portfolio. A favorable outcome could further strengthen its competitive position in the CGRP market.
• Neutral Sentiment: Dividend maintained: AbbVie declared a quarterly dividend of $1.73 per share, payable November 16 to shareholders of record October 15. The declaration reinforces the income appeal of ABBV but does not represent a new increase in the payout.
• Neutral Sentiment: Analyst confidence remains favorable: HSBC raised its price target to $315 from $300 while maintaining a Buy rating, reflecting optimism about AbbVie’s newer growth products and pipeline.
• Negative Sentiment: Ongoing concentration concerns: Investors continue to monitor AbbVie’s reliance on Skyrizi and Rinvoq to offset Humira’s patent-related decline. The stock’s elevated valuation also leaves less room for disappointment if pipeline launches or immunology growth slow.

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is currently owned by corporate insiders.

AbbVie Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott's diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie's immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.